Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Finished Goods (2016 - 2025)

Guided Therapeutics' Finished Goods history spans 15 years, with the latest figure at $43000.0 for Q1 2025.

  • For Q1 2025, Finished Goods fell 2.27% year-over-year to $43000.0; the TTM value through Mar 2025 reached $43000.0, down 2.27%, while the annual FY2024 figure was $43000.0, 94.74% down from the prior year.
  • Finished Goods for Q1 2025 was $43000.0 at Guided Therapeutics, roughly flat from $43000.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $818000.0 in Q4 2022 and bottomed at $22000.0 in Q2 2021.
  • The 5-year median for Finished Goods is $44000.0 (2023), against an average of $261941.2.
  • The largest annual shift saw Finished Goods plummeted 97.37% in 2021 before it surged 2456.25% in 2022.
  • A 5-year view of Finished Goods shows it stood at $32000.0 in 2021, then soared by 2456.25% to $818000.0 in 2022, then changed by 0.0% to $818000.0 in 2023, then tumbled by 94.74% to $43000.0 in 2024, then changed by 0.0% to $43000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Finished Goods are $43000.0 (Q1 2025), $43000.0 (Q4 2024), and $44000.0 (Q3 2024).